Literature DB >> 10708747

Identification of a vascular endothelial growth factor (VEGF) antagonist, sFlt-1, from a human hematopoietic cell line NALM-16.

T Inoue1, K Kibata, M Suzuki, S Nakamura, R Motoda, K Orita.   

Abstract

An antagonistic activity against vascular endothelial growth factor (VEGF) was identified in the culture supernatants of certain human hematopoietic cell lines and the antagonistic protein was purified from NALM-16 (B cell) culture supernatant. Amino acid sequencing of the N-terminus and Western blot analysis confirmed that the antagonist was identical to a soluble truncated form of Flt-1 (sFlt-1). Seventeen of 52 leukemia and lymphoma cell lines investigated expressed sFlt-1 mRNA, and 16 of the sFlt-1 expressing cells also expressed VEGF and membrane-bound Flt-1 (mFlt-1). This report is the first showing that sFlt-1 can be produced by malignant hematopoietic cells, suggesting that the production of VEGF antagonist by hematopoietic cells may play some role in the regulation of VEGF activity in normal and malignant hematopoietic cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708747     DOI: 10.1016/s0014-5793(00)01246-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  Purified protein derivative of tuberculin upregulates the expression of vascular endothelial growth factor in T lymphocytes in vitro.

Authors:  Wataru Matsuyama; Ryuji Kubota; Teruto Hashiguchi; Hiroaki Momi; Masaharu Kawabata; Masanori Nakagawa; Kimiyoshi Arimura; Mitsuhiro Osame
Journal:  Immunology       Date:  2002-05       Impact factor: 7.397

2.  Clinical significance of serum levels of vascular endothelial growth factor and its receptor in biliary disease and carcinoma.

Authors:  Munechika Enjoji; Makoto Nakamuta; Koji Yamaguchi; Satoshi Ohta; Kazuhiro Kotoh; Marie Fukushima; Masami Kuniyoshi; Tomomi Yamada; Masao Tanaka; Hajime Nawata
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

3.  Soluble VEGFR1 signaling guides vascular patterns into dense branching morphologies.

Authors:  Dóra Lakatos; Ellák Somfai; Előd Méhes; András Czirók
Journal:  J Theor Biol       Date:  2018-08-04       Impact factor: 2.691

Review 4.  Positive and Negative Regulation of Angiogenesis by Soluble Vascular Endothelial Growth Factor Receptor-1.

Authors:  Cristina M Failla; Miriam Carbo; Veronica Morea
Journal:  Int J Mol Sci       Date:  2018-04-27       Impact factor: 5.923

Review 5.  Modulation of Receptor Tyrosine Kinase Activity through Alternative Splicing of Ligands and Receptors in the VEGF-A/VEGFR Axis.

Authors:  Megan Stevens; Sebastian Oltean
Journal:  Cells       Date:  2019-03-28       Impact factor: 6.600

6.  FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells.

Authors:  Tao Jia; Thibault Jacquet; Fabien Dalonneau; Pauline Coudert; Elisabeth Vaganay; Chloé Exbrayat-Héritier; Julien Vollaire; Véronique Josserand; Florence Ruggiero; Jean-Luc Coll; Béatrice Eymin
Journal:  BMC Biol       Date:  2021-08-25       Impact factor: 7.431

7.  Neuropilin-1 is required for endothelial cell adhesion to soluble vascular endothelial growth factor receptor 1.

Authors:  Gianni Colotti; Cristina Maria Failla; Pedro Miguel Lacal; Mariangela Ungarelli; Federica Ruffini; Patrizio Di Micco; Angela Orecchia; Veronica Morea
Journal:  FEBS J       Date:  2021-08-27       Impact factor: 5.622

8.  Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma.

Authors:  Masatoshi Jinnin; Damian Medici; Lucy Park; Nisha Limaye; Yanqiu Liu; Elisa Boscolo; Joyce Bischoff; Miikka Vikkula; Eileen Boye; Bjorn R Olsen
Journal:  Nat Med       Date:  2008-10-19       Impact factor: 53.440

9.  Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells.

Authors:  Mary T Chou; Jing Wang; Donald J Fujita
Journal:  BMC Biochem       Date:  2002-12-31       Impact factor: 4.059

10.  Potential therapeutic strategies for non - muscle invasive bladder cancer based on association of intravesical immunotherapy with p - mapa and systemic administration of cisplatin and doxorubicin.

Authors:  Queila Cristina Dias; Iseu da Silva Nunes; Patrick Vianna Garcia; Wagner Jose Favaro
Journal:  Int Braz J Urol       Date:  2016 Sep-Oct       Impact factor: 1.541

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.